Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - NextCure, Inc. | nxtc-20201231ex32153ca18.htm |
| EX-31.2 - EX-31.2 - NextCure, Inc. | nxtc-20201231ex312946c86.htm |
| EX-31.1 - EX-31.1 - NextCure, Inc. | nxtc-20201231ex3110601f6.htm |
| EX-24.1 - EX-24.1 - NextCure, Inc. | nxtc-20201231ex2415f3b92.htm |
| EX-10.3 - EX-10.3 - NextCure, Inc. | nxtc-20201231ex10322e166.htm |
| 10-K - 10-K - NextCure, Inc. | nxtc-20201231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-8 No. 333-231438) pertaining to the NextCure, Inc. 2019 Employee Stock Purchase Plan; and |
| (2) | Registration Statement (Form S-8 No. 333-231436) pertaining to the NextCure, Inc. 2015 Omnibus Incentive Plan and the NextCure, Inc. 2019 Omnibus Incentive Plan; |
of our report dated March 4, 2021, with respect to the financial statements of NextCure, Inc. included in this Annual Report (Form 10-K) of NextCure, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP | |
| |
Baltimore, Maryland | |
March 4, 2021 | |